IGAN - IGA NEPHROPATHY
Clinical trials for IGAN - IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGAN - IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGAN - IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a gene-silencing drug calm overactive complement in kidney disease?
Disease control Not yet recruitingThis phase II trial tests an experimental drug called QLS7305 in people with several kidney diseases driven by overactivation of the complement system, a part of the immune system. The drug is a small interfering RNA (siRNA) designed to reduce production of complement protein C3,…
Matched conditions: IGAN - IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…
Matched conditions: IGAN - IGA NEPHROPATHY
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC